From SBA-financed asset purchases to earnouts tied to prescription file retention — here's how buyers and sellers structure pharmacy transactions that actually close.
Acquiring an independent pharmacy is rarely a straightforward business purchase. The transaction must account for the prescription file as a standalone asset, inventory priced separately at cost, DEA and state board license transfers, PBM contract change-of-ownership provisions, and the very real risk that patients don't follow the new owner. Because of this complexity, pharmacy deals in the $1M–$5M revenue range most commonly use asset purchase structures financed with SBA 7(a) loans, often layered with seller carry notes and earnout provisions tied to patient retention metrics. Understanding how each financing and structural component works — and why it matters in a pharmacy context — is essential for both buyers negotiating their first ownership opportunity and retiring pharmacist-owners trying to maximize exit value.
Find Pharmacy Businesses For SaleAsset Purchase with Prescription File and Inventory Priced Separately
The dominant deal structure in independent pharmacy acquisitions. The buyer purchases specific business assets — primarily the prescription file, fixtures, equipment, and goodwill — while inventory is priced at cost at closing via a physical count. This structure allows buyers to avoid assuming unknown liabilities and gives both parties a clean framework for transferring DEA registrations and state board licenses to the new entity.
Pros
Cons
Best for: First-time pharmacist-buyers using SBA financing, existing independent operators acquiring a second location, and any transaction where the seller wants a clean exit without ongoing business ties.
SBA 7(a) Loan with Seller Carry Note
The most common financing stack for independent pharmacy acquisitions under $5M in enterprise value. The buyer secures an SBA 7(a) loan — typically covering 70–80% of the purchase price — while the seller carries a subordinated note for 10–20% of the deal. The buyer contributes a 10% cash equity injection. The seller note is usually subordinated to the SBA loan and may include a standby period during which no payments are made to the seller.
Pros
Cons
Best for: Licensed pharmacists acquiring their first independent pharmacy, buyers with strong clinical backgrounds but limited acquisition capital, and sellers with bankable financials willing to accept some deferred consideration.
Earnout Tied to Prescription Volume and Patient File Retention
An earnout structure defers a portion of the purchase price — typically 10–25% — contingent on the pharmacy retaining a defined percentage of active patients and prescription volume over a 12–24 month period post-close. Earnout metrics are usually tied to 30-day refill rates, active patient count thresholds, or total prescription volume compared to the trailing 12-month baseline established during due diligence.
Pros
Cons
Best for: Transactions where the prescription file represents the majority of deal value, where the seller is retiring and patient relationships are highly personal, or where there is meaningful uncertainty about PBM contract continuity post-close.
Full Cash or Strategic Buyer Acquisition
Private equity-backed pharmacy platforms and regional pharmacy chains acquiring independent locations for roll-up purposes often transact with all-cash or near-cash structures, bypassing SBA financing entirely. These buyers can close faster, underwrite higher multiples for specialty or compounding pharmacies with strong recurring revenue, and absorb the operational complexity of DEA and license transfers within existing compliance infrastructure.
Pros
Cons
Best for: Specialty, compounding, or long-term care pharmacies with above-average EBITDA margins, clean compliance records, and revenue streams that reduce PBM dependency — particularly attractive to PE-backed roll-up platforms.
Retiring Pharmacist Selling a Community Retail Pharmacy — SBA + Seller Carry
$1,800,000
SBA 7(a) loan: $1,260,000 (70%); Seller carry note: $360,000 (20%); Buyer cash equity injection: $180,000 (10%). Inventory of $120,000 priced separately at cost and paid at close from buyer's working capital.
SBA loan at 10-year term, WSJ Prime + 2.75%; seller note subordinated, 6% interest, 24-month SBA standby period followed by 36-month amortization. No earnout. Prescription file valued at $1,400,000 based on 18-month trailing script revenue; goodwill and equipment comprising the balance.
Compounding Pharmacy Acquisition with Patient Retention Earnout
$2,500,000 base plus up to $400,000 earnout
SBA 7(a) loan: $1,750,000 (70% of base); Seller carry note: $375,000 (15%); Buyer equity: $375,000 (15%). Earnout of up to $400,000 paid in two tranches: $200,000 at month 12 if active compounding patient count is at or above 85% of pre-close baseline, and $200,000 at month 24 if 30-day refill rate on compounded scripts remains above 62%.
SBA loan at 10-year term; seller note at 5.5% with 18-month standby then 48-month repayment. Earnout measured against audited dispensing records provided monthly to seller. Seller agrees to a 90-day transition and 12-month non-compete within 15-mile radius.
PE-Backed Platform Acquiring a Long-Term Care Pharmacy
$4,200,000
All cash at close: $4,200,000. No SBA financing. Inventory of $280,000 included in purchase price based on pre-close third-party count. Accounts receivable excluded; seller retains pre-close AR with a 90-day collection window.
Asset purchase agreement. Seller required to remain as consulting pharmacist for 6 months post-close at $12,000/month to support LTC facility contract retention and staff integration. 24-month non-compete, 36-month non-solicit of LTC facility clients. Valuation based on 5.2x trailing 12-month EBITDA of $807,000.
Find Pharmacy Businesses For Sale
Pre-screened targets ready for your deal structure — free to join.
Pharmacy inventory is a dynamic, perishable asset that changes in value daily based on drug costs, expiration dates, and formulary shifts. Pricing it separately at a physical count conducted at or just before close ensures the buyer pays only for saleable stock at actual replacement cost — typically wholesale acquisition cost or invoice price. Including inventory in the headline purchase price creates disputes and incentivizes sellers to run down stock before closing or buyers to discount aggressively. Most SBA lenders also require separate inventory treatment to properly collateralize the deal.
Most PBM contracts include change-of-ownership provisions that require the buyer to apply for new credentialing as a separate participating provider. This process can take 60–120 days depending on the PBM — and during that window, the pharmacy may not be reimbursable under the new owner's NPI. Buyers must plan for a transition period where the seller's entity remains open under their credentials while the buyer's credentialing is processed, which requires careful legal coordination and is one of the primary reasons pharmacy deals take 4–6 months from LOI to close.
A prescription file is typically valued as a multiple of trailing 12-month prescription revenue, adjusted for active patient count, 30-day refill rates, payer mix, and DIR fee exposure. In practice, prescription files in healthy independent pharmacies trade at 0.8–1.5x annual script revenue, with files featuring high refill rates, diversified payer mix, and specialty or compounding volume commanding the top of that range. Files heavily concentrated in low-margin generics with high DIR fee exposure trade at the low end. Buyers should always obtain a dispensing data export going back 24 months to validate the file's active patient count before agreeing to a file valuation.
No. SBA 7(a) loans require a minimum 10% equity injection from the buyer. In practice, most pharmacy lenders require 10–15% buyer equity plus may require a seller carry note of 10–20% to bridge valuation gaps or demonstrate seller confidence. The SBA loan itself covers the remainder, up to the $5M program maximum. Buyers should expect to bring $150,000–$500,000 in cash to a typical independent pharmacy acquisition in the $1.5M–$3.5M purchase price range, depending on lender requirements and deal structure.
The DEA registration is not transferable — the buyer must apply for a new DEA registration for their entity before they can legally receive or dispense controlled substances. The application is submitted to the DEA's Diversion Control Division and typically takes 4–8 weeks, though processing times vary. Until the new registration is issued, the buyer cannot accept controlled substance inventory transfers or fill controlled prescriptions under their license. Deals must be structured to account for this gap, either by timing close to coincide with DEA approval or arranging for the seller to operate temporarily under a management agreement while the buyer's registration processes.
Earnouts appear in roughly 30–40% of independent pharmacy transactions and are most useful when there is genuine uncertainty about patient retention post-transition — particularly in pharmacies where the owner has deep personal relationships with patients. They work best when the metrics are simple, measurable, and tied to data the buyer already tracks in their dispensing system (active patient count, 30-day refill rates, total prescription volume). Earnouts break down when the metrics are ambiguous, when the seller has no ongoing role to influence outcomes, or when external factors like PBM network changes affect volume independently of patient loyalty. Sellers should push for clearly defined measurement methodology and dispute resolution procedures before agreeing to any earnout structure.
More Pharmacy Guides
More Deal Structure Guides
Find the right target, structure the deal, and close with confidence.
Create your free accountNo credit card required
For Buyers
For Sellers